AbbVie Q3 2026 Earnings: EPS More Than Doubles Year Over Year
AbbVie posted strong third-quarter 2026 results, with both GAAP and adjusted diluted EPS surging more than 100% despite a modest IPR&D headwind.
AbbVie reported third-quarter 2026 financial results Friday, disclosing that diluted earnings per share on a GAAP basis reached $2.37, a gain of more than 100 percent compared with the same period a year earlier. Adjusted diluted EPS came in at $3.82, also more than doubling year over year, signaling broad-based profit momentum at the pharmaceutical giant.
The results were not without a drag. Management noted an unfavorable impact of $0.11 per share tied to acquired in-process research and development costs and milestones expense, which weighed modestly on both GAAP and adjusted figures. Such charges are common in the biopharmaceutical sector when companies absorb pipeline assets through licensing or acquisition agreements.
Read more NatGold Digital Delists NATG Token From MEXC After U.S. Treasury Action →
The magnitude of the year-over-year EPS increase — exceeding 100 percent on both reporting bases — points to a substantial improvement in underlying profitability, whether driven by revenue growth, margin expansion, or a combination of the two. AbbVie has been working to diversify its portfolio beyond legacy products as it navigates a competitive landscape that includes biosimilar pressure on mature franchises.
The quarterly report marks a closely watched data point for investors tracking AbbVie's long-term earnings trajectory following significant pipeline and commercial investments. Details on revenue by product, full-year guidance, and management commentary are available in the complete earnings release.
Continue reading at Earnings.
